Announcement PDF ASX Announcement 13 January 2020 ASX Market Announcements ASX Limited Level 4 Stock Exchange Centre 20 Bridge Street Sydney NSW 2000 Appointment of New Director Melbourne, Australia, January 13, 2020 – Avecho Biotechnology Limited (ASX: AVE), an Australian drug delivery company, is pleased to announce the appointment of Matthew Patrick McNamara as a Non-Executive Director of the Company, effective 13 January 2020. Matt McNamara has over 30 years’ experience in the healthcare and medical sciences sector. Matt has a BSc (Hons) in Molecular Biology and is also a holder of an MBA. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd. He has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co. The Board welcomes Matt McNamara to Avecho Biotechnology Limited and believes that his extensive expertise in the healthcare and medical sciences sector will be a tremendous asset for the Company. For enquiries, please contact Dr Greg Collier Avecho Biotechnology Limited +61 3 9002 5000 Email: gcollier@avecho.com.au This announcement is authorsed for release to the market by the Board of Directors of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited (ASX:AVE) develops and commercialises innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM ® (Targeted Penetration Matrix). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s major projects include delivering TPM® enhanced patches, gels and injectable products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. See more here - http://avecho.com.au/ Avecho Biotechnology Limited | ASX:AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au